Compare Palantir Technologies Inc (PLTR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Repligen Corporation Common Stock — how do they compare? Palantir Technologies Inc trades at $197.81 (market cap $501.45B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Palantir Technologies Inc is far larger — about 45× Repligen Corporation Common Stock's market cap, and Palantir Technologies Inc is more actively traded (18,438,992 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 79 Days and Repligen Corporation Common Stock for 0 Days on average.
| PLTR | RGEN | |
|---|---|---|
Market Cap | $501.45B | $11.14B |
Volume | 18,438,992 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $209.05 | $194.57 |
52-Week Low | $107.27 | $102.87 |
Typical Hold Time | 79 Days | 0 Days |
Enterprise Value | $492.25B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $200.97, down 3.84% on the day but maintains strong bullish technical momentum with consecutive earnings beats. The company demonstrates exceptional fundamental performance with 56.2% revenue growth in 2025, reaching $4.48 billion, and net income margin expanding to 36.3%. Recent partnership with Armada for sovereign AI infrastructure and consistent analyst optimism highlight the stock's growth trajectory despite premium valuation metrics.
Outlook remains positive with accelerating AI adoption driving growth, though elevated P/E of 178.35 presents valuation risk. Wall Street consensus targets $195.86 with 54% buy ratings, while technical indicators show potential resistance near $213-$219 levels. Key risks include growth normalization and competitive pressures in the expanding AI software market.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
